Zobrazeno 1 - 10
of 13
pro vyhledávání: '"63"'
Autor:
Noriko Ueno, Ryo Matoba, Ichiro Takemasa, Koji Umeshita, Hiroaki Nagano, Morito Monden, Yukinori Kurokawa, Shin Ishii, Shoji Nakamori, Keizo Dono, Kikuya Kato, Masato Sakon
Publikováno v:
Clinical Cancer Research. 10:6029-6038
Purpose: The prognosis of hepatocellular carcinoma (HCC) is very poor, particularly in patients with tumors that have invaded the major branches of the portal vein. Combination chemotherapy with intra-arterial 5-fluorouracil and subcutaneous interfer
Autor:
Gunnar B. Kristensen, Tord Hompland, Unn Beate Salberg, Tina S. Evensen, Eva-Katrine Aarnes, Kjersti V. Lund, Heidi Lyng, Tiril Hillestad, Vilde E. Skingen, Anja Nilsen, Trond Stokke, Christina S. Fjeldbo
Publikováno v:
Cancer Research. 80:3993-4003
Tumor hypoxia levels range from mild to severe and have different biological and therapeutical consequences but are not easily assessable in patients. Here we present a method based on diagnostic dynamic contrast enhanced (DCE) MRI that reflects a co
Autor:
David R. Spigel, Julie Cordova, Michael S. Gordon, Stephanie Royer-Joo, YounJeong Choi, Vanessa Lemahieu, Joan H. Schiller, David E. Gerber, Randall C. Dere, David S. Shames, Maria Martinez Garcia, Anjali Vaze, Enriqueta Felip, Jian Xu, Valerie Westcott, Robert Kahn, Eva Schuth, Sarah B. Goldberg, Daniel J. Maslyar, Katie Wood, Yulei Wang, Jeffrey R. Infante, Eric W. Humke, Kedan Lin, Howard A. Burris, Miguel Martin, Divya Samineni
Publikováno v:
Clinical Cancer Research. 26:364-372
Purpose: This phase I trial assessed the safety, tolerability, and preliminary antitumor activity of lifastuzumab vedotin (LIFA), an antibody–drug conjugate of anti-NaPi2b mAb (MNIB2126A) and a potent antimitotic agent (monomethyl auristatin E). Pa
Autor:
Komal Jhaveri, David M. Hyman, Richard Bryce, Melanie E. Dujka, Sarina Anne Piha-Paul, David I. Quinn, Ingrid A. Mayer, Cristina Saura, David B. Solit, Gary A. Ulaner, Seta Shahin, Ben Stone, Grace Mann, Funda Meric-Bernstam
Publikováno v:
Clin Cancer Res
Purpose: To determine whether FDG PET can expand eligibility in biomarker-selected clinical trials by providing a means to quantitate response in patients with non-assessable disease by RECIST. Experimental Design: SUMMIT (NCT01953926) is a multicent
Autor:
Matthew A. Gubens, Branimir I. Sikic, David Smith, Jakob Dupont, Robert Joseph Stagg, Ann M. Kapoun, George M Manikhas, Peter D. Eisenberg, Lu Xu, Rashmi Chugh
Publikováno v:
Clinical Cancer Research. 20:6295-6303
Purpose: This phase I trial evaluated the safety, pharmacokinetics, and pharmacodynamics of demcizumab (OMP-21M18), a humanized IgG2 mAb targeting the Notch ligand DLL4 in adult patients with advanced malignancies. Experimental Design: Standard 3+3 d
Autor:
Christopher D. Lao, Wallace Akerley, Jeffrey A. Sosman, Lawrence E. Flaherty, Kim Margolin, Vernon K. Sondak, James C. Moon, John M. Kirkwood, Megan Othus
Publikováno v:
Clinical Cancer Research. 18:1129-1137
Purpose: Signaling pathway stimulation by activating mutations of oncogenes occurs in most melanomas and can provide excellent targets for therapy, but the short-term therapeutic success is limited by intrinsic and acquired resistance. The mitogen-ac
Autor:
Mary-Ellen Taplin, Arturo Molina, Glenn J. Bubley, Christopher M. Haqq, Eric J. Small, Christopher J. Logothetis, Thian Kheoh, Shreya Shah, Matthew R. Smith, Charles J. Ryan, Christine Kilian, Eleni Efstathiou
Publikováno v:
Clinical Cancer Research. 17:4854-4861
Purpose: Abiraterone is an oral inhibitor of CYP17, which is essential for androgen biosynthesis. This multicenter study assessed its efficacy in patients with castration-resistant prostate cancer (CRPC), without prior chemotherapy or CYP17-targeted
Autor:
Shyam Biswal, John D. Minna, Ignacio I. Wistuba, Carmen Behrens, Stephen G. Swisher, Luisa M. Solis, B. Nebiyou Bekele, Wenli Dong, Milind Suraokar, Cesar A. Moran, David J. Stewart, Alejandro H. Corvalan, Natalie C. Ozburn
Publikováno v:
Clinical Cancer Research. 16:3743-3753
Purpose: To understand the role of nuclear factor erythroid-2–related factor 2 (Nrf2) and Kelch-like ECH-associated protein 1 (Keap1) in non–small cell lung cancer (NSCLC), we studied their expression in a large series of tumors with annotated cl
Autor:
David B. Alexander, Masaaki Iigo, Gen Iinuma, Daizo Saito, Takahiro Kozu, Tadao Kakizoe, Yasuo Ohashi, Takayuki Akasu, Hiroyuki Tsuda, Yutaka Saito
Publikováno v:
Cancer Prevention Research. 2:975-983
Lactoferrin (LF), a secreted, iron binding glycoprotein originally discovered as a component of milk, is found in a variety of exocrine secretions and in the secondary granules of polymorphonuclear leukocytes. Animal experiments have shown that oral
Autor:
Nobuyuki Katakami, Hiroshige Yoshioka, Koji Takeda, Masahiro Fukuoka, Masaki Miyazaki, Takashi Nishimura, Akihito Kubo, Isamu Okamoto, Shunichi Sugawara, Kazuhiko Nakagawa, Noriyuki Ebi
Publikováno v:
Clinical Cancer Research. 14:5250-5254
Purpose: To evaluate the efficacy and toxicity of combination therapy with the oral fluoropyrimidine formulation S-1 and irinotecan for patients with advanced NSCLC. Experimental Design: Chemotherapy-naive patients with advanced NSCLC were treated wi